160 related articles for article (PubMed ID: 11240741)
1. Adenosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53 and mdm-2 analysis of 11 cases.
Blom R; Guerrieri C
Int J Gynecol Cancer; 1999 Jan; 9(1):37-43. PubMed ID: 11240741
[TBL] [Abstract][Full Text] [Related]
2. Endometrial stromal sarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 17 cases.
Blom R; Malmström H; Guerrieri C
Int J Gynecol Cancer; 1999 Mar; 9(2):98-104. PubMed ID: 11240749
[TBL] [Abstract][Full Text] [Related]
3. Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma.
Gallardo A; Prat J
Am J Surg Pathol; 2009 Feb; 33(2):278-88. PubMed ID: 18941402
[TBL] [Abstract][Full Text] [Related]
4. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654
[TBL] [Abstract][Full Text] [Related]
5. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
6. High-grade Müllerian Adenosarcoma: Genomic and Clinicopathologic Characterization of a Distinct Neoplasm With Prevalent TP53 Pathway Alterations and Aggressive Behavior.
Hodgson A; Amemiya Y; Seth A; Djordjevic B; Parra-Herran C
Am J Surg Pathol; 2017 Nov; 41(11):1513-1522. PubMed ID: 28834809
[TBL] [Abstract][Full Text] [Related]
7. Mesodermal (müllerian) adenosarcoma of the ovary: a clinicopathologic analysis of 40 cases and a review of the literature.
Eichhorn JH; Young RH; Clement PB; Scully RE
Am J Surg Pathol; 2002 Oct; 26(10):1243-58. PubMed ID: 12360039
[TBL] [Abstract][Full Text] [Related]
8. Cluster of uterine mullerian adenosarcoma in the Washington, DC metropolitan area with high incidence of sarcomatous overgrowth.
Seidman JD; Wasserman CS; Aye LM; MacKoul PJ; O'Leary TJ
Am J Surg Pathol; 1999 Jul; 23(7):809-14. PubMed ID: 10403304
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical markers and the clinical course of adenosarcoma: a series of seven cases.
Omi M; Tonooka A; Chiba T; Tanaka Y; Fusegi A; Aoki Y; Nomura H; Kanao H; Takazawa Y
Diagn Pathol; 2020 Sep; 15(1):119. PubMed ID: 32972432
[TBL] [Abstract][Full Text] [Related]
10. Müllerian adenosarcomas of the uterus with sarcomatous overgrowth. A clinicopathological analysis of 10 cases.
Clement PB
Am J Surg Pathol; 1989 Jan; 13(1):28-38. PubMed ID: 2535774
[TBL] [Abstract][Full Text] [Related]
11. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
[TBL] [Abstract][Full Text] [Related]
12. Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors.
Momeni Boroujeni A; Kertowidjojo E; Wu X; Soslow RA; Chiang S; Da Silva EM; Weigelt B; Chui MH
Mod Pathol; 2022 Nov; 35(11):1684-1694. PubMed ID: 36138078
[TBL] [Abstract][Full Text] [Related]
13. Primary extra-uterine and extra-ovarian mullerian adenosarcoma: case report and literature review.
Mandato VD; Torricelli F; Mastrofilippo V; Valli R; Aguzzoli L; La Sala GB
BMC Cancer; 2018 Feb; 18(1):134. PubMed ID: 29402239
[TBL] [Abstract][Full Text] [Related]
14. Uterine Adenosarcoma.
Ulrich UA; Denschlag D
Oncol Res Treat; 2018; 41(11):693-696. PubMed ID: 30326467
[TBL] [Abstract][Full Text] [Related]
15. [Prognosis-related clinicopathologic characteristics of FIGO stage Ⅰ Müllerian adenosarcoma of uterus].
Wang Y; Liu AJ; Chen X; Song X
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):334-338. PubMed ID: 29783798
[No Abstract] [Full Text] [Related]
16. Genomewide copy number analysis of Müllerian adenosarcoma identified chromosomal instability in the aggressive subgroup.
Lee JC; Lu TP; Changou CA; Liang CW; Huang HN; Lauria A; Huang HY; Lin CY; Chiang YC; Davidson B; Lin MC; Kuo KT
Mod Pathol; 2016 Sep; 29(9):1070-82. PubMed ID: 27255164
[TBL] [Abstract][Full Text] [Related]
17. The Overexpression of Programmed Death-Ligand 2 in Uterine Adenosarcoma: Correlation with High-Grade Morphology, Mutant Type TP53 Expression and Clinical Outcomes.
Ok Atılgan A; Yılmaz Akçay E; Özen Ö; Haberal Reyhan AN; Ayhan A
Int J Surg Pathol; 2023 Jun; 31(4):352-364. PubMed ID: 35466759
[TBL] [Abstract][Full Text] [Related]
18. Uterine Adenosarcoma: a Review.
Nathenson MJ; Ravi V; Fleming N; Wang WL; Conley A
Curr Oncol Rep; 2016 Nov; 18(11):68. PubMed ID: 27718181
[TBL] [Abstract][Full Text] [Related]
19. Management of uterine adenosarcomas with and without sarcomatous overgrowth.
Tanner EJ; Toussaint T; Leitao MM; Hensley ML; Soslow RA; Gardner GJ; Jewell EL
Gynecol Oncol; 2013 Apr; 129(1):140-4. PubMed ID: 23283300
[TBL] [Abstract][Full Text] [Related]
20. Müllerian adenosarcoma of the uterine cervix with sarcomatous overgrowth: A case report of aggressive disease in a young patient.
Morales F DA; Medina R ML; Trujillo LM; Beltrán MI; Dulcey IC
Int J Surg Case Rep; 2016; 27():155-161. PubMed ID: 27621097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
